Regional governments around the world hope to become significant players in the world
biotechnology industry through their support for local clusters. This article explores whether …

This Editorial introduces the Special Issue on 'Biotechnology Clusters and Beyond'. Drawing
on the interventions of five commissioned articles from Canada, Germany, Israel, the UK and …

Competitive advantage in the biotech industry depends on several key factors: the existence
of vibrant academic institutions (Kenney 1986), venture capital and other forms of risk …

Today, US biotechnology firms dominate the growing therapeutics and diagnostics sectors
despite most of the key discoveries being made by European, and especially UK scientists …

As the economy has globalized, it has also regionalized, which has led to the integration of
different spaces across different scales. A number of theories contend that the endogenous …

This paper updates to 2006 material first gathered in the late 1990s. Though Germany has
about the same number of firms as the UK its biotechnology economy is far weaker, with …

Despite the widespread interest of national, regional and local governments in promoting
their own biotechnology industry, it is now well known that this sector exhibits …

This paper's focus is on both the geography of entrepreneurship and on industry‐
collaborative links internationally, nationally and at the local level in the UK biotech industry …

Government policies across the world seek to create clusters of companies and other
stakeholders that specialise in a particular technology to build an 'industrial ecosystem'. This …

Differences in growth patterns between regional clusters are often attributed to the extent to
which they benefit from agglomeration, defined as the advantages that derive from being …